TY - JOUR
T1 - Ethical considerations in global HIV phylogenetic research
AU - Ethics in HIV Phylogenetics Working Group
AU - Coltart, Cordelia E.M.
AU - Hoppe, Anne
AU - Parker, Michael
AU - Dawson, Liza
AU - Amon, Joseph J.
AU - Simwinga, Musonda
AU - Geller, Gail
AU - Henderson, Gail
AU - Laeyendecker, Oliver
AU - Tucker, Joseph D.
AU - Eba, Patrick
AU - Novitsky, Vladimir
AU - Vandamme, Anne Mieke
AU - Seeley, Janet
AU - Dallabetta, Gina
AU - Harling, Guy
AU - Grabowski, M. Kate
AU - Godfrey-Faussett, Peter
AU - Fraser, Christophe
AU - Cohen, Myron S.
AU - Pillay, Deenan
AU - Baggaley, Rachel
AU - Bernard, Edwin J.
AU - Burns, David
AU - Dedes, Nikos
AU - Delpech, Valerie
AU - German, Danielle
AU - Grabowksi, M. Kate
AU - Hall, Irene
AU - Kozlakidis, Zisis
AU - Mwanza, Felix
AU - Reis, Andreas
AU - Simwanga, Musonda
AU - Wertheim, Joel O.
AU - Zimmerman, Rick
N1 - Funding Information:
This work was funded by the Bill & Melinda Gates Foundation and done with support from the HIV Prevention Trials Network and the PANGEA-HIV project (grant code OPP1084362). CEMC is funded by the Wellcome Trust (grant code 106551/Z/14/A). OL received additional support from the Division of Intramural Research National Institute of Allergy and Infectious Diseases. A-MV received funding from Fonds voor Wetenschappelijk Onderzoek—Flanders (grant G.0692.14), and the VIROGENESIS project receives funding from the European Union's Horizon 2020 Research and Innovation Programme (under grant agreement 634650). GD is employed by the Bill & Melinda Gates Foundation. LD is employed by the US National Institutes of Health. DP is funded by the Wellcome Trust. No other funding sources or representatives thereof had any role in the writing of the manuscript or the decision to submit it for publication. None of the authors have been paid to write this Review by a pharmaceutical company or other agency. The views expressed in this Review do not represent any policy or position of the US Department of Health and Human Services or any of its components. All other authors declare no competing interests.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Phylogenetic analysis of pathogens is an increasingly powerful way to reduce the spread of epidemics, including HIV. As a result, phylogenetic approaches are becoming embedded in public health and research programmes, as well as outbreak responses, presenting unique ethical, legal, and social issues that are not adequately addressed by existing bioethics literature. We formed a multidisciplinary working group to explore the ethical issues arising from the design of, conduct in, and use of results from HIV phylogenetic studies, and to propose recommendations to minimise the associated risks to both individuals and groups. We identified eight key ethical domains, within which we highlighted factors that make HIV phylogenetic research unique. In this Review, we endeavoured to provide a framework to assist researchers, public health practitioners, and funding institutions to ensure that HIV phylogenetic studies are designed, done, and disseminated in an ethical manner. Our conclusions also have broader relevance for pathogen phylogenetics.
AB - Phylogenetic analysis of pathogens is an increasingly powerful way to reduce the spread of epidemics, including HIV. As a result, phylogenetic approaches are becoming embedded in public health and research programmes, as well as outbreak responses, presenting unique ethical, legal, and social issues that are not adequately addressed by existing bioethics literature. We formed a multidisciplinary working group to explore the ethical issues arising from the design of, conduct in, and use of results from HIV phylogenetic studies, and to propose recommendations to minimise the associated risks to both individuals and groups. We identified eight key ethical domains, within which we highlighted factors that make HIV phylogenetic research unique. In this Review, we endeavoured to provide a framework to assist researchers, public health practitioners, and funding institutions to ensure that HIV phylogenetic studies are designed, done, and disseminated in an ethical manner. Our conclusions also have broader relevance for pathogen phylogenetics.
UR - http://www.scopus.com/inward/record.url?scp=85057172173&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057172173&partnerID=8YFLogxK
U2 - 10.1016/S2352-3018(18)30134-6
DO - 10.1016/S2352-3018(18)30134-6
M3 - Review article
C2 - 30174214
AN - SCOPUS:85057172173
VL - 5
SP - e656-e666
JO - The Lancet HIV
JF - The Lancet HIV
SN - 2352-3018
IS - 11
ER -